Please upgrade your browser.
Nephrectomy is the gold standard, but ablative therapies are gaining acceptance in specific situations of renal cell carcinoma. Source: Urology Times
Freezing tumors may help relieve the extreme pain of cancer that has spread to the bone, which is often untouched by narcotics or radiation, U.S. researchers said on Tuesday. This freezing process, called cryoablation, is often used to destroy kidney, prostate and other tumors, but researchers at the Mayo Clinic in Rochester, Minnesota, found it eased cancer pain in 80 percent of patients in a small study, and the effect lasted for up to six months.
Cleveland BioLabs has initiated a Phase II efficacy study for Curaxin CBLC102 in advanced renal cell carcinoma at ClinWorks Cancer Research Center in Charlotte, North Carolina.
Argos Therapeutics Presents Positive Data on its Personalized Cancer Immunotherapy Programs at ISTBC Meeting
Argos Therapeutics today announced the presentation of two abstracts related to its personalized dendritic cell-based immunotherapy programs at the 22nd Annual Meeting of the International Society for the Biological Treatment of Cancer (iSTBc), held November 2-4 in Boston. Results from the presented abstracts reveal that Argos' immunotherapeutic candidate AGS-003 is compatible in combination with sunitinib (Sutent(R)) for the treatment of renal cell carcinoma (RCC).
Pfizer Inc's (PFE.N: Quote, Profile, Research) experimental drug axitinib has shown promise for treating patients with advanced kidney cancer, slowing the disease for six months or more in some cases, according to a study published on Tuesday. Source: Reuters, Pfizer Inc.
EntreMed, Inc. , a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the presentation of results for its cell cycle inhibitor, MKC-1, in preclinical renal cell carcinoma (RCC) models. The results were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in San Francisco, California. Source: EntreMed, Inc
Exelixis, Inc. today reported encouraging data from an ongoing phase 2 trial of XL880, an inhibitor of MET and VEGFR2 kinases, in patients with papillary renal cell carcinoma (PRC). Of 19 patients with measurable disease evaluable for tumor responses, 15 (79%) have had a decrease in tumor size (4-33%), including one patient with a partial response. All 19 evaluable patients with at least one post-baseline tumor assessment have had stable disease for at least three months, including 12 patients with stable disease for six months to 15+ months. Results of preliminary analyses of plasma biomarkers and tumor samples are consistent with inhibition of angiogenesis and proliferation and an increase in apoptosis. Data were presented today in a poster session (Abstract #B249) at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, which is being held October 22-26, 2007 in San Francisco. Source: PRNewswire-FirstCall
Intradigm Study Shows Ability of siRNAs Systemically Delivered With TargeTran(TM) System to Suppress Tumor-Induced Angiogenesis in Mice
Intradigm Corporation, a leading developer of targeted, systemic RNA interference (RNAi) therapeutics, today announced study results that demonstrated the company's TargeTran(TM) delivery system is capable of delivering vascular endothelial growth factor (VEGF) targeted small interfering RNAs (siRNAs) that suppress tumor-induced angiogenesis by silencing target gene expression in mice. The study findings support the preclinical development of ICS-283 a nanoparticle-based compound comprised of siRNAs that target both VEGF and its main receptor. Complete study findings were presented by Intradigm scientists today at the 2007 AACR- NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. Source: PRNewswire
Results of RTA 402 Phase I Cancer Trial Presented at AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
Reata Pharmaceuticals, Inc. announced today the presentation of results from a Phase I cancer trial of its lead Antioxidant Inflammation Modulator (AIM), RTA 402, in a poster session at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference in San Francisco, CA. A first-in-class targeted therapy, RTA 402 inhibits the activity of two transcription factors, NF-kappa B and STAT3, that play a central role in cancer progression, metastasis, and resistance to therapy. Source: Reata Pharmaceuticals, Inc.
|Powered by NeonCRM|